公开(公告)号：US11813246B2

公开(公告)日：2023-11-14

申请号：US17313312

申请日：2021-05-06

Applicant: AstraZeneca AB ,  Array BioPharma, Inc.

Inventor： Nicola Frances Bateman ,  Paul Richard Gellert ,  Kathryn Jane Hill

IPC: A61K31/4184 ,  A61K9/14 ,  A61K9/48 ,  C07D235/06 ,  A61K47/36 ,  A61K9/00 ,  A61K47/22

CPC classification number: A61K31/4184 ,  A61K9/0053 ,  A61K9/145 ,  A61K9/146 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/22 ,  A61K47/36 ,  C07D235/06

Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.

公开(公告)号：US11780835B2

公开(公告)日：2023-10-10

申请号：US17376571

申请日：2021-07-15

Applicant: Array BioPharma Inc.

Inventor： Ronald Jay Hinklin ,  Shelley Allen ,  Patrick Barbour ,  Adam Cook ,  Joshua Dahlke ,  John Gaudino ,  Ellen Laird ,  Oren T. McNulty ,  Qian Zhao

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

公开(公告)号：US20230234955A1

公开(公告)日：2023-07-27

申请号：US17941367

申请日：2022-09-09

Applicant: Array BioPharma Inc.

Inventor： Julia Haas ,  Steven W. Andrews ,  Yutong Jiang ,  Gan Zhang

IPC: C07D487/04 ,  C07D519/00 ,  A61P29/00 ,  A61K31/5377 ,  A61K9/00 ,  C07D471/04 ,  A61K31/519 ,  A61K45/06

CPC classification number: C07D487/04 ,  C07D519/00 ,  A61P29/00 ,  A61K31/5377 ,  A61K9/0053 ,  C07D471/04 ,  A61K31/519 ,  A61K45/06 ,  Y02A50/30

Abstract: Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenarative disease or Typanosoma cruzi infection in a mammal.

公开(公告)号：US20230190749A1

公开(公告)日：2023-06-22

申请号：US17975709

申请日：2022-10-28

Applicant: Array BioPharma Inc.

Inventor： Patrice A. Lee ,  Shannon L. Winski ,  Kevin Koch

IPC: A61K31/517 ,  A61K45/06 ,  A61P35/04 ,  A61P35/00 ,  A61K31/337 ,  A61K31/7068

CPC classification number: A61K31/517 ,  A61K45/06 ,  A61P35/04 ,  A61P35/00 ,  A61K31/337 ,  A61K31/7068

Abstract: Compounds for the treatment of brain cancer are provided herein. Pharmaceutical compositions comprised of those compounds for the treatment of brain cancer are also provided herein.

公开(公告)号：US20230097309A1

公开(公告)日：2023-03-30

申请号：US17895951

申请日：2022-08-25

Applicant: ARRAY BIOPHARMA INC.

Inventor： David Shank Fry ,  Christopher M. Lindemann ,  Michael Preigh ,  Corey Jay Bloom ,  Christopher Donovan Craig ,  Devon Brevard Dubose ,  Jeff Gautschi ,  Dan Smithey

IPC: A61K31/517 ,  A61K9/10 ,  A61K9/16 ,  A61K47/38 ,  A61K9/20 ,  A61K47/32 ,  A61K9/00

Abstract: A solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and processes for preparing the solid dispersion are provided herein. Also, a pharmaceutical composition comprising a solid dispersion of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine and uses thereof are provided herein.

公开(公告)号：US20230044943A1

公开(公告)日：2023-02-09

申请号：US17745136

申请日：2022-05-16

Applicant: ARRAY BIOPHARMA INC.

Inventor： Giordano Caponigro ,  Zhu Alexander Cao

IPC: A61K31/4184 ,  A61K31/506 ,  A61K39/395 ,  A61P35/04 ,  A61K45/06 ,  A61K31/573 ,  A61P35/00 ,  C07K16/28 ,  A61K9/00

Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.

公开(公告)号：US11571424B2

公开(公告)日：2023-02-07

申请号：US16942094

申请日：2020-07-29

Applicant: Array BioPharma Inc.

Inventor： Donald T. Corson ,  Christopher M. Lindemann ,  Daniel J. Watson

IPC: A61K31/517 ,  A61K31/437 ,  A61P35/00 ,  C07D471/04 ,  A61K45/06

Abstract: Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

公开(公告)号：US20230023851A1

公开(公告)日：2023-01-26

申请号：US17362580

申请日：2021-06-29

Applicant: Array BioPharma Inc.

Inventor： Mark Laurence BOYS ,  Bryan Daniel ELLIS ,  John Joseph GAUDINO ,  Erik James HICKEN ,  Ellen Ruth LAIRD ,  Nicholas Charles LAZZARA ,  Bradley Jon NEWHOUSE ,  Spencer Phillip PAJK

IPC: C07D487/04 ,  C07D519/00 ,  A61K45/06

Abstract: This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US11414404B2

公开(公告)日：2022-08-16

申请号：US16910688

申请日：2020-06-24

Applicant: Array BioPharma Inc.

Inventor： Patrick Michael Barbour ,  Katie Keaton Brown ,  Adam Wade Cook ,  Erik James Hicken ,  Dean Russell Kahn ,  Ellen Ruth Laird ,  Andrew Terrance Metcalf ,  David Austin Moreno ,  Bradley Jon Newhouse ,  Spencer Phillip Pajk ,  Brett Joseph Prigaro ,  Li Ren ,  Eugene Tarlton

IPC: C07D403/12 ,  C07D239/90 ,  C07D239/91 ,  A61K31/4184 ,  A61K45/06

Abstract: Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X1, R1, R2, R3, R4, R5 and R6 are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

公开(公告)号：US11376239B2

公开(公告)日：2022-07-05

申请号：US16580505

申请日：2019-09-24

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Zhu Alexander Cao

IPC: A61K31/4184 ,  A61K31/506 ,  A61K39/395 ,  A61P35/04 ,  A61K45/06 ,  A61K31/573 ,  A61P35/00 ,  C07K16/28 ,  A61K9/00 ,  A61K39/00

Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.